Cargando…
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model
ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length sequence (Wuhan-1). AZD1222 was shown to have 74% vaccine efficacy (VE) against symptomatic disease in clinical trials and ov...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863164/ https://www.ncbi.nlm.nih.gov/pubmed/35194602 http://dx.doi.org/10.21203/rs.3.rs-1343927/v1 |
_version_ | 1784655180231344128 |
---|---|
author | van Doremalen, Neeltje Schulz, Jonathan E. Adney, Danielle R. Saturday, Taylor A. Fischer, Robert J. Yinda, Claude Kwe Thakur, Nazia Newman, Joseph Ulaszewska, Marta Belij-Rammerstorfer, Sandra Saturday, Greg Spencer, Alexandra J. Bailey, Dalan Gilbert, Sarah C. Lambe, Teresa Munster, Vincent J. |
author_facet | van Doremalen, Neeltje Schulz, Jonathan E. Adney, Danielle R. Saturday, Taylor A. Fischer, Robert J. Yinda, Claude Kwe Thakur, Nazia Newman, Joseph Ulaszewska, Marta Belij-Rammerstorfer, Sandra Saturday, Greg Spencer, Alexandra J. Bailey, Dalan Gilbert, Sarah C. Lambe, Teresa Munster, Vincent J. |
author_sort | van Doremalen, Neeltje |
collection | PubMed |
description | ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length sequence (Wuhan-1). AZD1222 was shown to have 74% vaccine efficacy (VE) against symptomatic disease in clinical trials and over 2.5 billion doses of vaccine have been released for worldwide use. However, SARS-CoV-2 continues to circulate and consequently, variants of concern (VoCs) have been detected, with substitutions in the S protein that are associated with a reduction in virus neutralizing antibody titer. Updating vaccines to include S proteins of VoCs may be beneficial over boosting with vaccines encoding the ancestral S protein, even though current real-world data is suggesting good efficacy against hospitalization and death following boosting with vaccines encoding the ancestral S protein. Using the Syrian hamster model, we evaluated the effect of a single dose of AZD2816, encoding the S protein of the Beta VoC, and efficacy of AZD1222/AZD2816 as a heterologous primary series against challenge with the Beta or Delta variant. We then investigated the efficacy of a single dose of AZD2816 or AZD1222 against the Omicron VoC. As seen previously, minimal to no viral sgRNA could be detected in lungs of vaccinated animals obtained at 5 days post inoculation, in contrast to lungs of control animals. Thus, these vaccination regimens are protective against the Beta, Delta, and Omicron VoCs in the hamster model. |
format | Online Article Text |
id | pubmed-8863164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Journal Experts |
record_format | MEDLINE/PubMed |
spelling | pubmed-88631642022-02-23 Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model van Doremalen, Neeltje Schulz, Jonathan E. Adney, Danielle R. Saturday, Taylor A. Fischer, Robert J. Yinda, Claude Kwe Thakur, Nazia Newman, Joseph Ulaszewska, Marta Belij-Rammerstorfer, Sandra Saturday, Greg Spencer, Alexandra J. Bailey, Dalan Gilbert, Sarah C. Lambe, Teresa Munster, Vincent J. Res Sq Article ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length sequence (Wuhan-1). AZD1222 was shown to have 74% vaccine efficacy (VE) against symptomatic disease in clinical trials and over 2.5 billion doses of vaccine have been released for worldwide use. However, SARS-CoV-2 continues to circulate and consequently, variants of concern (VoCs) have been detected, with substitutions in the S protein that are associated with a reduction in virus neutralizing antibody titer. Updating vaccines to include S proteins of VoCs may be beneficial over boosting with vaccines encoding the ancestral S protein, even though current real-world data is suggesting good efficacy against hospitalization and death following boosting with vaccines encoding the ancestral S protein. Using the Syrian hamster model, we evaluated the effect of a single dose of AZD2816, encoding the S protein of the Beta VoC, and efficacy of AZD1222/AZD2816 as a heterologous primary series against challenge with the Beta or Delta variant. We then investigated the efficacy of a single dose of AZD2816 or AZD1222 against the Omicron VoC. As seen previously, minimal to no viral sgRNA could be detected in lungs of vaccinated animals obtained at 5 days post inoculation, in contrast to lungs of control animals. Thus, these vaccination regimens are protective against the Beta, Delta, and Omicron VoCs in the hamster model. American Journal Experts 2022-02-15 /pmc/articles/PMC8863164/ /pubmed/35194602 http://dx.doi.org/10.21203/rs.3.rs-1343927/v1 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article van Doremalen, Neeltje Schulz, Jonathan E. Adney, Danielle R. Saturday, Taylor A. Fischer, Robert J. Yinda, Claude Kwe Thakur, Nazia Newman, Joseph Ulaszewska, Marta Belij-Rammerstorfer, Sandra Saturday, Greg Spencer, Alexandra J. Bailey, Dalan Gilbert, Sarah C. Lambe, Teresa Munster, Vincent J. Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model |
title | Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model |
title_full | Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model |
title_fullStr | Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model |
title_full_unstemmed | Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model |
title_short | Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model |
title_sort | efficacy of chadox1 vaccines against sars-cov-2 variants of concern beta, delta and omicron in the syrian hamster model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863164/ https://www.ncbi.nlm.nih.gov/pubmed/35194602 http://dx.doi.org/10.21203/rs.3.rs-1343927/v1 |
work_keys_str_mv | AT vandoremalenneeltje efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT schulzjonathane efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT adneydanieller efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT saturdaytaylora efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT fischerrobertj efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT yindaclaudekwe efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT thakurnazia efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT newmanjoseph efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT ulaszewskamarta efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT belijrammerstorfersandra efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT saturdaygreg efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT spenceralexandraj efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT baileydalan efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT gilbertsarahc efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT lambeteresa efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel AT munstervincentj efficacyofchadox1vaccinesagainstsarscov2variantsofconcernbetadeltaandomicroninthesyrianhamstermodel |